$13.88
2.36% day before yesterday
Nasdaq, Jul 25, 10:12 pm CET
ISIN
US81734D1046
Symbol
SEPN
Reports
Quarter | Annual
Sector
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals

Septerna Stock price

$13.88
+3.15 29.36% 1M
-2.28 14.11% 6M
-9.02 39.39% YTD
-4.12 22.89% 1Y
-4.12 22.89% 3Y
-4.12 22.89% 5Y
-4.12 22.89% 10Y
-4.12 22.89% 20Y
Nasdaq, Closing price Fri, Jul 25 2025
+0.32 2.36%
ISIN
US81734D1046
Symbol
SEPN
Reports
Quarter | Annual
Sector
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals

Key metrics

Basic
Market capitalization
$618.5m
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | 16.1
P/S
479.4 | 16.3
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
92.0%
Return on Equity
-17.1%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$1.3m | $37.9m
EBITDA
$-104.9m | $-104.0m
EBIT
$-106.7m | $-115.7m
Net Income
$-93.3m | -
Free Cash Flow
$-93.3m
Growth (TTM | estimate)
Revenue
- | 3,413.3%
EBITDA
- | -31.0%
EBIT
- | -43.2%
Net Income
- | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
-8,109.4% | -274.2%
EBIT
-8,248.3%
Net
-7,208.2% | -
Free Cash Flow
-7,210.1%
More
EPS
$-2.1
FCF per Share
-
Short interest
12.4%
Employees
-
Rev per Employee
-
Show more

Is Septerna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Septerna Stock Analysis

Unlock Scores for Free

Dividends

??

High-Growth-Investing

HGI

??

Levermann

???

Analyst Opinions

11 Analysts have issued a Septerna forecast:

9x Buy
82%
2x Hold
18%
More details on Analyst Estimates Including Price Targets

Analyst Opinions

11 Analysts have issued a Septerna forecast:

Buy
82%
Hold
18%
Analyst Estimates with Stock Price Targets

Financial data from Septerna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.29 1.29
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
-
1,816%
- Research and Development Expense 85 85
-
6,559%
-105 -105
-
-8,135%
- Depreciation and Amortization 1.80 1.80
-
140%
EBIT (Operating Income) EBIT -107 -107
-
-8,274%
Net Profit -93 -93
-
-7,230%

In millions USD.

Don't miss a Thing! We will send you all news about Septerna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Septerna Stock News

Neutral
GlobeNewsWire
●
about 2 months ago
Septerna to Present at Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D.
Negative
MarketBeat
●
2 months ago
Analysts Think These Stocks Could More Than Double in Value
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.
Positive
Seeking Alpha
●
2 months ago
Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist
Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company's innovative GPCR platform and deep pipeline are promising, yet early clinical setbacks and fierce competition raise execution risks. Septerna's cash position is solid for now, but future clinical expenses may require ...
More Septerna News

Company Profile

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jeffrey Finer
Website septerna.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now
The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today